Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FGEQ3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $48,807
Award facts
- Contract value 100% obligated
- $48,806.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $48,806.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. This delivery order, issued on December 18, 2025, with an ultimate completion date of December 19, 2025, contains no set-aside designation and represents a direct purchase under the company's existing Indefinite Delivery Contract with DLA. DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy that establishes regional prime vendor contractors to support Department of Defense pharmaceutical supply requirements.
The delivery order supports DLA's Medical Supply Chain division in fulfilling recurring pharmaceutical needs for military healthcare facilities. DMS Pharmaceutical Group's qualification as a PPV-G GEN V prime vendor, evidenced by its single-award indefinite delivery contract with a $499.999 billion ceiling value and completion date of December 31, 2036, positions the company to deliver a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables. The company's established performance across multiple delivery orders demonstrates its capability to meet the specialized pharmaceutical requirements of the federal military medical system without requiring subcontractor involvement.
Quick answers
Who was awarded contract SPE2DR26FGEQ3?
SPE2DR26FGEQ3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FGEQ3 worth?
The government has obligated $48,807 on SPE2DR26FGEQ3.
Is contract SPE2DR26FGEQ3 an order under another contract?
Yes. SPE2DR26FGEQ3 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGEQ3 competed?
The extent of competition for SPE2DR26FGEQ3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award